iSpecimen (ISPC) AI Stock Analysis

• Market Cap: $6.36M
• Dividend Yield: N/A
• Average Volume (3M): 8.88M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.31
• Revenue Growth: -43.77%
• EPS Growth: 55.78%
• Country: US
• Employees: 24
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.42
• Shares Outstanding: 9,771,028
• 10 Day Avg. Volume: 698,577
• 30 Day Avg. Volume: 8,882,166
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.57
• Price to Sales (P/S): 0.20
• P/FCF Ratio: -0.23
• Enterprise Value/Market Cap: 0.34
• Enterprise Value/Revenue: 0.36
• Enterprise Value/Gross Profit: 1.11
• Enterprise Value/Ebitda: -0.27
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $1.00 ▲(56.25% Upside)

The overall stock score is primarily influenced by weak financial performance and poor valuation metrics. The technical analysis indicates bearish momentum, further impacting the score negatively. The lack of earnings call data and corporate events means these factors did not contribute to the score.

iSpecimen Business Overview & Revenue Model

Company Description

iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.

How the Company Makes Money

iSpecimen makes money primarily through its marketplace platform, which facilitates the procurement of human biospecimens for research purposes. The company generates revenue by charging fees for matching researchers with biospecimen suppliers and for providing logistical services in the collection and delivery of specimens. Additionally, iSpecimen may earn through subscription or transaction-based models with its partners in the healthcare and biobanking sectors. Strategic partnerships with healthcare institutions and biobanks further enhance its revenue-generating capabilities by expanding its access to a wide range of sample types and increasing the platform's attractiveness to researchers.

iSpecimen Financial Statement Overview

Summary

iSpecimen faces significant financial challenges, including declining revenues, negative profitability, and cash flow issues. Despite some improvements in the balance sheet with reduced debt levels and improved equity ratios, the company's financial health remains weak, with persistent net losses and cash flow deficits.

Income Statement

The company has shown a declining trend in revenue and profitability. Gross Profit Margin decreased from 52.8% in 2020 to 42.9% in 2024. Net Profit Margins remain negative, with worsening EBIT and EBITDA margins, indicating operational inefficiency. Revenue has been declining from $11.13 million in 2021 to $9.29 million in 2024, showcasing negative growth.

Balance Sheet

The balance sheet reflects a relatively high level of debt with a Debt-to-Equity Ratio of 0.09 in 2024, reduced from previous years. However, the negative equity in prior years raises concerns about financial stability. The equity ratio improved to 35.4% in 2024 from negative figures in earlier years, indicating some improvement in financial health.

Cash Flow

The company has consistently negative operating and free cash flows, with a significant cash burn. The operating cash flow to net income ratio is negative, highlighting issues in converting income into cash. Although free cash flow improved slightly in 2024 compared to previous years, it remains negative, indicating continued challenges in liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.91M	9.29M	9.93M	10.40M	11.14M	8.18M
Gross Profit	1.93M	3.99M	5.11M	5.65M	5.89M	4.60M
EBITDA	-8.00M	-12.73M	-8.80M	-8.80M	-5.86M	-1.74M
Net Income	-10.19M	-12.50M	-11.10M	-9.04M	-10.02M	-6.76M
Balance Sheet
Total Assets	6.03M	9.35M	15.82M	24.62M	35.72M	6.21M
Cash, Cash Equivalents and Short-Term Investments	588.77K	1.88M	5.01M	15.31M	27.74M	695.91K
Total Debt	287.88K	312.17K	196.24K	185.85K	3.42M	12.77M
Total Liabilities	5.41M	6.04M	6.08M	4.31M	5.93M	33.49M
Stockholders Equity	621.97K	3.31M	9.74M	20.31M	29.79M	-27.28M
Cash Flow
Free Cash Flow	-6.19M	-8.30M	-10.55M	-9.01M	-11.71M	-1.39M
Operating Cash Flow	-5.94M	-8.26M	-5.81M	-5.82M	-10.67M	-288.38K
Investing Cash Flow	-253.47K	1.98M	-7.23M	-3.19M	-1.04M	-1.10M
Financing Cash Flow	4.63M	5.82M	70.89K	-3.42M	38.75M	2.03M

iSpecimen Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.64
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ISPC, the sentiment is Negative. The current price of 0.64 is below the 20-day moving average (MA) of 0.76, below the 50-day MA of 1.05, and below the 200-day MA of 1.23, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 34.62 is Neutral, neither overbought nor oversold. The STOCH value of 23.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ISPC.

iSpecimen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MYNZ	42 Neutral	$7.52M	―	―	―	―	―
ISPC	41 Neutral	$6.36M	-0.07	-303.74%	―	-43.77%	55.78%
INBS	39 Underperform	$7.00M	―	-186.64%	―	-1.90%	87.72%
BIAF	38 Underperform	$9.40M	-0.10	-1802.45%	―	4.99%	22.58%
CHEK	26 Underperform	$9.13M	―	―	―	―	―

iSpecimen Corporate Events

iSpecimen Approves Key Proposals in Stockholder Meeting

On October 30, 2025, iSpecimen Inc. held a special meeting of stockholders to vote on several key proposals. The company successfully approved a reverse stock split, an increase in authorized shares, and amendments related to private financing transactions and convertible securities, all of which are aimed at enhancing its financial flexibility and compliance with Nasdaq rules.

The most recent analyst rating on (ISPC) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on iSpecimen stock, see the ISPC Stock Forecast page.

iSpecimen Announces $200M Solana-Based Treasury Initiative

On September 4, 2025, iSpecimen Inc. announced an update on its strategic initiative to integrate digital assets into its business model by building a $200 million corporate treasury reserve based on the Solana blockchain ecosystem. Since its initial announcement in August 2025, the company has been approached by several cryptocurrency-related companies offering opportunities in tokenized real-world assets and highly ranked cryptocurrencies. iSpecimen plans to establish a SOL-based treasury program to diversify its balance sheet and support long-term growth, with a focus on a buy and HODL strategy and purchasing locked SOL at a discount. This initiative is expected to enhance shareholder value and allow for liquidity management through partial diversification and spot trading.

The most recent analyst rating on (ISPC) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on iSpecimen stock, see the ISPC Stock Forecast page.

iSpecimen Completes Milestone 1 in Digital Transformation

On August 21, 2025, iSpecimen Inc. announced the successful completion of Milestone 1 in its digital transformation program, which involved the installation of the Salestack platform and the provisioning of modern infrastructure. This milestone enhances the iSpecimen Marketplace® with a cloud-native architecture, improving reliability, security, and innovation capabilities, and sets the stage for the next phase of integration aimed at achieving end-to-end operational efficiency.

The most recent analyst rating on (ISPC) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on iSpecimen stock, see the ISPC Stock Forecast page.

iSpecimen Inc. Reports Q2 2025 Financial Results

iSpecimen Inc. is a technology-driven company that operates an online marketplace platform connecting medical researchers with biospecimen suppliers, primarily in North America. In its latest earnings report for the quarter ending June 30, 2025, iSpecimen Inc. reported a significant decrease in revenue compared to the previous year, with total revenue of $713,135, down from $2,863,679. The company also reported a net loss of $1,047,243 for the quarter, an improvement from the $2,109,024 loss in the same period last year. Key financial metrics indicate a challenging period for iSpecimen, with a notable decline in cash and cash equivalents to $588,775 from $1,878,408 at the end of 2024. The company has been actively working to reduce costs, including a significant reduction in workforce and technology expenses, in an effort to improve its financial position. Looking forward, iSpecimen’s management remains focused on increasing revenues and managing expenditures to ensure the company’s sustainability, although uncertainties remain regarding the success of these efforts.

iSpecimen Announces Strategic Digital Asset Initiative

On August 7, 2025, iSpecimen Inc. announced a strategic initiative to integrate digital assets into its business model by establishing a corporate treasury reserve of up to $200 million based on the Solana blockchain ecosystem. This move, supported by WestPark Capital and BlockArrow, aims to enhance iSpecimen’s technological leadership in the life sciences by leveraging Solana’s high throughput, low transaction costs, and robust security features, potentially positioning the company as a leader in digital asset adoption and innovation.

iSpecimen Completes $1.75M Private Placement Deal

On July 31, 2025, iSpecimen Inc. entered into a Securities Purchase Agreement with accredited investors, resulting in a private placement of 1,559,828 shares of common stock or pre-funded warrants, generating gross proceeds of approximately $1.75 million. The placement, which closed on August 4, 2025, was conducted in compliance with Nasdaq rules and involved WestPark Capital, Inc. as the exclusive placement agent. The company plans to allocate $500,000 of the net proceeds for marketing and advertising services, with the remainder used for working capital and general corporate purposes. Additionally, iSpecimen entered into a registration rights agreement to facilitate the resale of shares and a marketing agreement with IR Agency LLC to enhance its visibility in the financial community.